Core Viewpoint - Cuprina Holdings has entered a joint venture with Aiodine Laboratory to develop and market a novel iodine-based disinfectant solution aimed at treating chronic and acute wounds, as well as other antiseptic applications [1][2]. Company Overview - Cuprina Holdings is a biomedical company focused on products for chronic wounds, infertility, and cosmeceuticals [1]. - Aiodine Laboratory specializes in advanced iodine formulations for health, safety, and hygiene [7]. Joint Venture Details - The joint venture will focus on developing an antiseptic wound care formulation, disinfectants, and daily home-use antiseptics, with plans to evaluate additional applications in personal care, oral hygiene, and veterinary uses [2]. - Cuprina will handle global sales strategies, marketing campaigns, and distribution networks, while Aiodine will provide its proprietary iodine technology and technical expertise [3]. Product Efficacy - The iodine-based solution works by penetrating pathogens and damaging their structures, leading to their destruction [4]. - A study published in Wounds International showed significant wound healing and reduced infection in three out of four patients treated with the solution, indicating its potential safety and effectiveness compared to existing wound care solutions [4]. Market Potential - The global wound care market was valued at approximately US$21 billion in 2024 and is projected to reach US$36 billion by 2032 [5]. - The antiseptics and disinfectants market is expected to exceed US$48 million by 2027 [5].
Cuprina forms Joint Venture Company with Aiodine Laboratory to Develop and Market Novel Iodine-based Solution as New Wound Care Therapy